Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Seattle Genetics has started a Phase II trial to evaluate its antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) as a treatment for the patients suffering from relapsed or refractory CD30-positive non-Hodgkin lymphomas.
Subscribe to our email newsletter
The trial will also evaluate patients with diffuse large B-cell lymphoma, peripheral T-cell lymphoma and other less common lymphoma subtypes.
The trial will investigate the antitumor activity, duration of response and safety profile of Adcetris in these patients.
The company expects to recruit around 55 patients in various centers across the US.
Seattle Genetics chief medical officer Thomas Reynolds said this clinical trial is part of their comprehensive development plan to evaluate the potential of Adcetris in CD30-positive malignancies, building on the data they have generated in certain patients with Hodgkin lymphoma and systemic ALCL.
"We believe the targeting ability of Adcetris to CD30 provides opportunities in selected lymphoma subtypes," Reynolds said.